All

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
23 May 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...

Read the press release
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
9 May 2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that...

Read the press release
Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
9 May 2023

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, announces the...

Read the press release
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
25 April 2023

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has...

Read the press release
Sinay, an Ocean Tech Company raises 5 M€ to help maritime corporations reconcile business efficiency with ocean biodiversity
25 April 2023

Sinay, an Ocean Tech Company raises 5 M€ to help maritime corporations reconcile business efficiency with ocean biodiversity

Led by Seventure Partners’ Blue Forward Fund (France), in collaboration with Shift4Good (France and Singapore), Alpana Ventures (Switzerland), Normandie Littoral (France),...

Read the press release
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
24 April 2023

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma (EURONEXT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival...

Read the press release
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
20 April 2023

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates...

Read the press release
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
12 April 2023

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma

Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD...

Read the press release
Cerea Partners enters exclusive negotiations with Seventure Partners to acquire majority stake in Polaris
4 April 2023

Cerea Partners enters exclusive negotiations with Seventure Partners to acquire majority stake in Polaris

Cerea Partners, the investor-partner of the food & beverage universe companies, has entered into exclusive negotiations with a view to acquire a majority stake of Polaris...

Read the press release
MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers
1 February 2023

MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic...

Read more